Which term describes individuals who meet criteria for access to experimental therapies under regulatory programs?

• A. Drug Manufacturers
• B. Medical Oversight
• C. Public Health Threat
• D. Qualified Patients

Answer: (D)

Access to experimental therapies under regulatory programs is limited to those who meet specific criteria for eligibility, often because their condition is serious and there are no satisfactory approved options. The term that describes these individuals is qualified patients. They must have a life-threatening or severely debilitating condition and be eligible under the program’s rules, with appropriate medical oversight and regulatory approval to receive an investigational drug outside of a formal trial. This emphasizes the patient’s status as someone who qualifies for access under compassionate use or expanded access arrangements. Drug manufacturers are the sponsors and suppliers of the investigational product, medical oversight refers to the supervision involved in administering it, and a public health threat is not what determines eligibility for these programs.